Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications 17 June 2021 | Press release
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies 7 April 2021 | Press release
Niall Martin, Chief Executive Officer presented a company overview at LifeSci Partners Precision Oncology Day 17 February 2021 | Conferences
Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients 11 February 2021 | Press release
Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer 12 January 2021 | Press release
Graeme Smith (CSO), Helen Robinson (Head of Biology), Simon Boulton (VP Science Strategy) are speaking at the PARP & DDR Inhibitors Summit Digital January 26-28 2021 18 December 2020 | Conferences
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology 3 December 2020 | Press release
Artios attending 38th Annual J.P Morgan Healthcare Conference in San Francisco, January 12-16 2020 9 January 2020 | Announcement